Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

High-level expression and characterization of an anti-VEGF165 single-chain variable fragment (scFv) by small ubiquitin-related modifier fusion in Escherichia coli

Abstract

Antibodies currently constitute the most rapidly growing class of human therapeutics; however, the high-yield production of recombinant antibodies and antibody fragments is a real challenge. High expression of active single-chain antibody fragment (scFv) in Escherichia coli has not been successful, as the protein contains three intramolecular disulfide bonds that are difficult to form correctly in the bacterial intracellular environment. To solve this problem, we fused the scFv gene against VEGF165 with a small ubiquitin-related modifier gene (SUMO) by synthesizing an artificial SUMO–scFv fusion gene that was highly expressed in the BL21(DE3) strain. The optimal expression level of the soluble fusion protein, SUMO–scFv, was up to 28.5% of the total cellular protein. The fusion protein was purified by Ni nitrilotriacetic acid (NTA) affinity chromatography and cleaved by a SUMO-specific protease to obtain the native scFv, which was further purified by Ni-NTA affinity chromatography. The result of the high-performance liquid chromatography showed that the purity of the recombinant cleaved scFv was greater than 98%. The primary structure of the purified scFv was confirmed by N-terminal amino acid sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectroscopy analysis. In vitro activity assay demonstrated that the recombinant scFv could dose-dependently inhibit VEGF165-induced human umbilical vein-derived endothelial cell proliferation. The expression strategy presented in this study allows convenient high yield and easy purification of recombinant scFv with native sequences.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Byun J, Heard JM, Huh JE, Park SJ, Jung EA, Jeong JO, Gwon HC, Kim DK (2001) Efficient expression of the vascular endothelial growth factor gene in vitro and in vivo, using an adeno-associated virus vector. J Mol Cell Cardiol 33(2):295–305

  2. Chaudhuri JB (1994) Refolding recombinant proteins: process strategies and novel approaches. Ann NY Acad Sci 721:374–385

  3. Cohen AW, Carbajal JM, Schaeffer RC Jr (1999) VEGF stimulates tyrosine phosphorylation of beta-catenin and small-pore endothelial barrier dysfunction. Am J Physiol 277:2038–2049

  4. Fernandez M, Vizzutti F, Garcia-Pagan JC, Rodes J, Bosch J (2004) Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology 126:886–894

  5. Friguet B, Chaffotte AF, Djavadi-Ohaniance L, Goldberg ME (1985) Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods 77(2):305–319

  6. Huston JS, George AJ (2001) Engineered antibodies take center stage. Hum Antib 10:127–142

  7. Huston JS, Mudgett-Hunter M, Tai MS, McCartney J, Warren F, Haber E, Oppermann H (1991) Protein engineering of single-chain Fv analogs and fusion proteins. Methods Enzymol 203:46–88

  8. Johnson ES, Blobel G (1999) Cell cycle-regulated attachment of the ubiquitin-related protein SUMO to the yeast septins. J Cell Biol 147:981–994

  9. Kuliopulos A, Walsh J (1994) Production, purification and cleavage of tandem repeats of tandem proteins. J Am Chem Soc 116:4599–4607

  10. Lamsoul I, Lodewick J, Lebrun S, Brasseur R, Burny A, Gaynor RB, Bex F (2005) Exclusive ubiquitination and sumoylation on overlapping lysine residues mediate NF-kappaB activation by the human T-cell leukemia virus tax oncoprotein. Mol Cell Biol 25:10391–10406

  11. Lavallie ER, McCoy JM (1995) Gene fusion expression systems in Escherichia coli. Curr Opin Biotechnol 6:501–506

  12. Li SJ, Hochstrasser M (1999) A new protease required for cell-cycle progression in yeast. Nature 398:246–251

  13. Li SJ, Hochstrasser M (2003) The Ulp1 SUMO isopeptidase: distinct domains required for viability, nuclear envelope localization, and substrate specificity. J Cell Biol 160:1069–1081

  14. Lin Z, Lei H (2008) Identification of a neutralizing scFv binding to human vascular endothelial growth factor 165 (VEGF165) using a phage display antibody library. Appl Biochem Biotechnol 144:15–26

  15. Liew OW, Ching Chong JP, Yandle TG, Brennan SO (2005) Preparation of recombinant thioredoxin fused N-terminal proCNP: analysis of enterokinase cleavage products reveals new enterokinase cleavage sites. Protein Expr Purif 41:332–340

  16. Loll PJ (2003) Membrane protein structural biology: the high throughput challenge. J Struct Biol 142:144–153

  17. Malakhov MP, Mattern MR, Malakhova OA, Drinker M, Weeks SD, Butt TR (2004) SUMO fusions and SUMO-specific protease for efficient expression and purification of proteins. J Struct Funct Genomics 5:75–86

  18. Marblestone JG, Edavettal SC, Lim Y, Lim P, Zuo X, Butt TR (2006) Comparison of SUMO fusion technology with traditional gene fusion systems: enhanced expression and solubility with SUMO. Protein Sci 15:182–189

  19. Rando RF, Notkins AL (1994) Production of human monoclonal antibodies against rabies virus. Lyssaviruses. Springer, Berlin, pp 195–205

  20. Yokota T, Milenic DE, Whitlow M, Schlom J (1992) Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52:3402–3408

Download references

Acknowledgments

This work was supported by grants from Scientific and Technological Program of Zhejiang Province (2006C33075; to Prof. Zhihua Lin).

Author information

Correspondence to Zhihua Lin.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ye, T., Lin, Z. & Lei, H. High-level expression and characterization of an anti-VEGF165 single-chain variable fragment (scFv) by small ubiquitin-related modifier fusion in Escherichia coli . Appl Microbiol Biotechnol 81, 311–317 (2008). https://doi.org/10.1007/s00253-008-1655-3

Download citation

Keywords

  • Vascular endothelial growth factor
  • scFv
  • Small ubiquitin-related modifier
  • Purification